December 2022 in “International Journal of Biomedicine”
This review discusses the potential role of androgens in COVID-19's pathophysiology and their possible link to hair disorders, but reports no new clinical results.
This study found no significant difference in CAG repeat numbers of the androgen receptor gene between Han Chinese women with female pattern hair loss and healthy controls, suggesting it may not be a genetic marker for FPHL in this population.
3 citations
,
October 2021 in “Indian Journal of Plastic Surgery”
The authors concluded that pattern hair loss is a complex condition with limited treatment efficacy and two FDA-approved drugs, finasteride and minoxidil, to slow its progression.
30 citations
,
March 2011 in “Australasian Journal of Dermatology”
This case report found that a woman's hair loss, which progressed while using spironolactone and topical minoxidil, reversed after switching to flutamide therapy.
54 citations
,
February 2010 in “British Journal of Dermatology”
This case report describes a patient with complete androgen insensitivity syndrome experiencing female pattern hair loss, suggesting that factors beyond direct androgen action may contribute to this condition in women.
The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
The user tried topical dutasteride for 6 months without success and is considering Pyrilutamide as an anti-androgen treatment for hair loss. Other users suggest using 1% Pyrilutamide and combining it with topical dutasteride.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
The conversation discusses hair loss treatments, including dutasteride, oral minoxidil, finasteride, and potential additions like topical finasteride, minoxidil, micro-needling, and topical anti-androgens such as RU58841. The effectiveness and worth of these treatments, including localized dutasteride mesotherapy, are considered.
The conversation discusses hair loss treatments, specifically the use of anti-androgens like RU58841 and Pyrilutamide, which are expensive in India. Alternatives like spironolactone and concerns about the effectiveness of finasteride and dutasteride are also mentioned.
Kintor Pharmaceutical: KX-826, a New Name in Hair Loss ResearchKX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.